Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).

Cellular and molecular biology (Noisy-le-Grand, France)

Volumn 43, Issue 7, 1997, Pages 1019-1029

  Mayhew, C ^a   Oakley, O ^a   Piper, J ^a   Hughes, N K ^a   Phillips, J ^a   Birch, N J ^a   Elford, H L ^a   Gallicchio, V S ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZAMIDOXIME; 3,4,5-TRIHYDROXYBENZAMIDOXIME; 3,4-DIHYDROXYBENZOHYDROXAMIC ACID; ANTIVIRUS AGENT; BENZAMIDINE DERIVATIVE; BIOLOGICAL MARKER; DIDANOSINE; HYDROXAMIC ACID; RIBONUCLEOTIDE REDUCTASE;

ANIMAL; ARTICLE; C57BL MOUSE; DISEASE COURSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; MORTALITY; MOUSE; MURINE LEUKEMIA VIRUS; PATHOPHYSIOLOGY; RODENT DISEASE; SURVIVAL RATE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDINES; BIOLOGICAL MARKERS; DIDANOSINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HYDROXAMIC ACIDS; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE;

EID: 0031261894     PISSN: 01455680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)